Statistically significant increasing trends were observed in the proportion of patients achieving the primary endpoint , @-joint count disease activity score with C reactive protein ( DAS@ ( CRP ) ) < @ ( @ % , @ % , @ % and @ % for @ , @ , @ or @mg/week MTX , respectively ) , DAS@ ( CRP ) < @ and American College of Rheumatology @/@/@ responses with increasing doses of MTX in combination with adalimumab .